<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638663</url>
  </required_header>
  <id_info>
    <org_study_id>SAFA-1-2012</org_study_id>
    <nct_id>NCT01638663</nct_id>
  </id_info>
  <brief_title>Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)</brief_title>
  <official_title>Effect of Vasopressin Antagonism on Renal Sodium and Water Handling and Circulation During Inhibition of the Nitric Oxide System in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of tolvaptan on renal water, sodium
      and potassium excretion, plasma concentration of vasoactive hormones,central blood pressure,
      pulse wave velocity (PWV) and augmentation index, basal and during inhibition of nitric oxide
      synthesis in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tolvaptan is a vasopressin antagonist (V2-antagonist) and is used in treatment of
      hyponatremia. Animal studies have demonstrated that inhibition of V2 receptors in the renal
      principal cell increases renal free water clearance and renal sodium excretion.

      Treatment with V2-receptor antagonists increases vasopressin concentration in plasma that
      stimulates V1-receptors in the vascular bed. This may change both central and peripheral
      hemodynamics and plasma concentration of vasoactive hormones. Changes in hemodynamics and
      hormone concentration may consequently change renal sodium and water handling.

      The nitric oxide system plays a central role in both renal sodium and water handling and
      regulation of vascular tone and blood pressure.

      The effects of tolvaptan the circulation and kidneys is investigated by using measurements of
      biomarkers specific for the sodium/water balance in the urine and by measurements of
      vasoactive hormones in the blood after administration of tolvaptan and L-NMMA infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CH2O</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of H2O clearance at baseline, during and after L-NMMA infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine biomarkers(Aquaporins, Epithelial Sodium Channels γ and β, Sodium/Chloride and Sodium/Potassium/Chloride cotransporter)</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central blood pressure</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive Hormones( Angiotensin II, Aldosterone, Endothelin, Atrial Natriuretic Peptide, Brain Natriuretic Peptide, Arginin Vasopressin)</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional sodium excretion</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of Sodium excretion at baseline, during and after L-NMMA infusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>Tolvaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of 15 mg Tolvaptan on each examination day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of 15 mg Unikalk tablet on each examination day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>15 mg pr day for 1 day</description>
    <arm_group_label>Tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet Unikalk 1 pr day for 1 day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Unikalk</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, age 18-40 years

          -  Body Mass Index (BMI) 18,5-30 kg/m2

        Exclusion Criteria:

          -  Anamnestic or clinical signs of heart, lung, lever, kidney and brain disease

          -  Neoplastic disease

          -  Drug abuse

          -  Alcohol abuse

          -  Medical treatment except peroral anticontraceptive

          -  Pregnancy

          -  Smoking

          -  Abnormal blood and urine sample

          -  Abnormal ECG

          -  Blood donation within a month before examination

          -  Arterial hypertension (&gt;140 mmHg systolic and/or 90 mmHg diastolic)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Safa Therwani, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicinsk Forskning</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Safa Therwani</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Professor, MD, Dr.Sci.</investigator_title>
  </responsible_party>
  <keyword>Tolvaptan</keyword>
  <keyword>L-NMMA</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>Nephrology</keyword>
  <keyword>Cardiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

